NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS)

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical firm, witnessed a 62% surge in its shares following positive Phase 3 BROADWAY clinical trial results. This trial assessed the efficacy of obicetrapib, an oral, non-statin cholesterol-lowering medication, in patients with cardiovascular disease and high low-density lipoprotein cholesterol (LDL-C) levels.

Trial Results

The trial met its primary endpoint, demonstrating a statistically significant LDL-C level reduction at day 84, achieving a 33% decrease compared to placebo. Additionally, there was a 21% reduction in major adverse cardiovascular events (MACE) observed at one year, although this was not a primary or secondary endpoint of the trial.

Safety Profile

Obicetrapib's safety profile was similar to that of placebo, with well-tolerated administration and safety results meeting expectations. Notably, the treatment discontinuation rate for the obicetrapib group was slightly lower than that of the placebo.

Leadership Comments

Dr. Michael Davidson, CEO, expressed pride in the results, confirming obicetrapib's efficacy and tolerability previously observed in Phase 2 trials. Dr. John Kastelein, Chief Scientific Officer, emphasized the clear safety profile and potential benefits of obicetrapib beyond just LDL-C lowering.

Trial Details

The BROADWAY trial was a 52-week, global, randomized, double-blind, placebo-controlled multicenter study, enrolling over 2,500 patients. It evaluated obicetrapib as an adjunct to maximally tolerated lipid-lowering therapies in patients with established atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH).

Future Plans

NewAmsterdam plans to present additional BROADWAY trial results at an upcoming medical conference and publish the findings in a major medical journal. The company also aims to discuss regulatory filings for obicetrapib, aiming to meet the global demand for effective LDL-C lowering therapies.

This announcement was based on a press release from NewAmsterdam Pharma Company.

This article was generated with AI support and edited for review. For more information, see our T&C.